These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17914081)

  • 41. Temozolomide: a novel oral alkylating agent.
    Danson SJ; Middleton MR
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
    Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
    Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Future directions for temozolomide therapy.
    Yung WK
    Semin Oncol; 2001 Aug; 28(4 Suppl 13):43-6. PubMed ID: 11550138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    J Clin Oncol; 2003 Sep; 21(17):3351-6. PubMed ID: 12947072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Eggermont AM; Kirkwood JM
    Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temozolomide for Treating Malignant Melanoma.
    Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
    J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medical treatment and other combination regimens.
    Bajetta E; Del Vecchio M; Bajetta R; Canova S
    Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
    [No Abstract]   [Full Text] [Related]  

  • 49. The efficacy of temozolomide for recurrent glioblastoma multiforme.
    Chen C; Xu T; Lu Y; Chen J; Wu S
    Eur J Neurol; 2013 Feb; 20(2):223-30. PubMed ID: 22680781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic chemotherapy for the treatment of metastatic melanoma.
    Li Y; McClay EF
    Semin Oncol; 2002 Oct; 29(5):413-26. PubMed ID: 12407507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of temozolomide in malignant brain tumours.
    Osoba D
    Lancet; 2000 Jul; 356(9226):342. PubMed ID: 11071219
    [No Abstract]   [Full Text] [Related]  

  • 54. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
    Treudler R; Georgieva J; Geilen CC; Orfanos CE
    J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
    Patel PM; Suciu S; Mortier L; Kruit WH; Robert C; Schadendorf D; Trefzer U; Punt CJ; Dummer R; Davidson N; Becker J; Conry R; Thompson JA; Hwu WJ; Engelen K; Agarwala SS; Keilholz U; Eggermont AM; Spatz A;
    Eur J Cancer; 2011 Jul; 47(10):1476-83. PubMed ID: 21600759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
    Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
    Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
    Ron IG; Sarid D; Ryvo L; Sapir EE; Schneebaum S; Metser U; Asna N; Inbar MJ; Safra T
    Melanoma Res; 2006 Feb; 16(1):65-9. PubMed ID: 16432458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
    Piperno-Neumann S; Diallo A; Etienne-Grimaldi MC; Bidard FC; Rodrigues M; Plancher C; Mariani P; Cassoux N; Decaudin D; Asselain B; Servois V
    Oncologist; 2016 Mar; 21(3):281-2. PubMed ID: 26911405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.